jakavi
novartis europharm limited - ruxolitiniib (fosfaadina) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastilised ained - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi on näidustatud ravi täiskasvanud patsientidel, kellel polycythaemia vera, kes on resistentsed või sallimatu hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
nplate
amgen europe b.v. - romiplostiim - idiopaatiline, trombotsütopeeniline purpur - antihemorraagilised ained - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroidid, immunoglobuliinid). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroidid, immunoglobuliinid).
besremi
aop orphan pharmaceuticals gmbh - ropeginterferon alfa-2b - polycythemia vera - immunostimulants, - besremi on näidustatud monotherapy täiskasvanute raviks, polycythaemia vera ilma sümptomaatiline splenomegaly.
nutriflex lipid 32/64 peri infusiooniemulsioon
b. braun melsungen ag - kombinatsioonid - infusiooniemulsioon - 1875ml 5tk; 1250ml 5tk
nutriflex lipid peri infusiooniemulsioon
b. braun melsungen ag - kombinatsioonid - infusiooniemulsioon - 1250ml 5tk; 1875ml 5tk; 2500ml 5tk
omegaven infusiooniemulsioon
fresenius kabi deutschland gmbh - rasvemulsioonid - infusiooniemulsioon - 50ml 10tk; 50ml 1tk; 100ml 1tk
lipidem infusiooniemulsioon
b. braun melsungen ag - rasvemulsioonid - infusiooniemulsioon - 200mg 1ml 250ml 1tk; 200mg 1ml 1000ml 1tk; 200mg 1ml 1000ml 6tk; 200mg 1ml 500ml 10tk; 200mg 1ml 250ml 10tk; 200mg 1ml 100ml 10tk; 200mg 1ml 1000ml 10tk
lipofundin mct/lct 20% infusiooniemulsioon
b. braun melsungen ag - rasvemulsioonid - infusiooniemulsioon - 20% 250ml 10tk; 20% 1000ml 6tk; 20% 500ml 10tk; 20% 100ml 10tk
videx ec gastroresistentne kõvakapsel
bristol-myers squibb gyogyszerkereskedelmi kft. - didanosiin - gastroresistentne kõvakapsel - 400mg 30tk
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.